[ad_1]
A new study published by the Lancet medical journal revealed that the Pfizer vaccine against the Corona virus protects people from hospitalization even with decreased effectiveness against infection over time, and researchers explained that the effectiveness of the Pfizer vaccine against Corona decreases 6 months after receiving two doses of the vaccine, according to what was published by the network cnbc American.
According to the study, the effectiveness of the Corona vaccine from Pfizer declines over several months, dropping to 47% after six months.
While the effectiveness of the Pfizer vaccine against infection diminishes over time, its protection from hospitalization when infected with corona continues, as the Pfizer vaccine protects against hospitalization with corona by 90% of all coronavirus variants of concern – including delta – for at least six months.
The results of the study, conducted by Pfizer in cooperation with Kaiser PermanenteEarly reports from the US Centers for Disease Control and Prevention found that protection against infection declines over several months.
Dr Sarah Tartoff, an epidemiologist and lead author of the study, said: ‘Protection against infection declines in the months following the second dose of Pfizer.
The published data comes less than two weeks after US health regulators agreed to distribute a booster dose of Pfizer’s vaccine to a group of Americans, including the elderly and other adults considered to be at high risk.
Study results were based on more than 3.4 million electronic health records from the Kaiser Permanente Southern California Health System between December 4 and August 8.
During the study period, the proportion of positive cases attributed to the delta variable increased from 0.6. % in April to nearly 87% by July.
The researchers found that the effectiveness of the Pfizer vaccine against delta variant infection was 93% one month after the second dose and decreased to 53% after four months.
By comparison, efficacy against variants other than delta was 97% after one month and dropped to 67% after four months, according to the study.
The researchers said that the efficacy against hospitalization associated with the delta variant remained high at 93% throughout the study period.
Dr. Louis Godard, chief medical officer of Pfizer Vaccines, said the decline in infection efficacy was “likely due to dwindling and not due to delta or other variables evading vaccine protection.”
“Our variant analysis clearly shows that the Pfizer vaccine is effective against all current variants of concern, including delta,” he said in a statement released alongside the study.
[ad_2]